$SCPX
Scorpius Holdings, Inc.

2015 Q3 Form 10-Q Financial Statement

#000155335015000845 Filed on August 13, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $0.00 $0.00 $6.546K
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $950.0K $890.0K $1.010M
YoY Change 14.46% -11.88% 129.55%
% of Gross Profit
Research & Development $677.2K $587.2K $849.4K
YoY Change -33.96% -30.86% 23.28%
% of Gross Profit
Depreciation & Amortization $30.44K $28.33K $18.90K
YoY Change 32.61% 49.88% 14436.92%
% of Gross Profit
Operating Expenses $5.343M $4.854M $2.977M
YoY Change 71.48% 63.03% 88.2%
Operating Profit -$5.343M -$4.854M -$2.977M
YoY Change 71.48% 63.03% 88.2%
Interest Expense $108.8K $73.08K
YoY Change 1237.36%
% of Operating Profit
Other Income/Expense, Net -$84.26K -$48.51K $19.08K
YoY Change 655.05% -354.29% -120.71%
Pretax Income -$5.430M -$4.900M -$2.960M
YoY Change 73.48% 65.54% 77.25%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.185M -$4.713M -$2.847M
YoY Change 72.83% 65.56% 75.65%
Net Earnings / Revenue -43490.91%
Basic Earnings Per Share
Diluted Earnings Per Share -$43.25 -$39.25 -$31.66
COMMON SHARES
Basic Shares Outstanding 8.405M shares 8.404M shares 6.452M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.00M $19.40M $16.80M
YoY Change -2.6% 15.48% 460.0%
Cash & Equivalents $8.211M $11.50M $5.983M
Short-Term Investments $6.700M $7.900M $10.90M
Other Short-Term Assets $1.000M $800.0K $700.0K
YoY Change 66.67% 14.29% 40.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $15.94M $20.20M $17.55M
YoY Change -0.92% 15.08% 396.89%
LONG-TERM ASSETS
Property, Plant & Equipment $468.0K $500.0K $480.9K
YoY Change 0.79% 3.97% 4788.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $254.3K $200.0K $21.05K
YoY Change 38.64% 850.12% -78.95%
Total Long-Term Assets $722.3K $800.0K $502.0K
YoY Change 11.51% 59.37% 732.8%
TOTAL ASSETS
Total Short-Term Assets $15.94M $20.20M $17.55M
Total Long-Term Assets $722.3K $800.0K $502.0K
Total Assets $16.66M $21.00M $18.05M
YoY Change -0.44% 16.31% 401.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $936.4K $800.0K $720.1K
YoY Change 37.6% 11.09% -45.4%
Accrued Expenses $2.074M $1.200M $320.1K
YoY Change 364.89% 274.88% 51.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.100M $1.000M
YoY Change 2000.0%
Total Short-Term Liabilities $5.064M $3.000M $1.040M
YoY Change 303.0% 188.39% -39.67%
LONG-TERM LIABILITIES
Long-Term Debt $2.800M $4.000M $0.00
YoY Change 154.55% -100.0%
Other Long-Term Liabilities $12.23K $12.23K
YoY Change
Total Long-Term Liabilities $12.23K $12.23K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.064M $3.000M $1.040M
Total Long-Term Liabilities $12.23K $12.23K $0.00
Total Liabilities $7.908M $6.000M $1.040M
YoY Change 241.59% 476.78% -58.26%
SHAREHOLDERS EQUITY
Retained Earnings -$37.94M -$32.76M
YoY Change
Common Stock $1.365K $975.00
YoY Change 39.43% 140.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.03M $15.00M $17.49M
YoY Change
Total Liabilities & Shareholders Equity $16.66M $21.00M $18.05M
YoY Change -0.44% 16.31% 401.15%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$5.185M -$4.713M -$2.847M
YoY Change 72.83% 65.56% 75.65%
Depreciation, Depletion And Amortization $30.44K $28.33K $18.90K
YoY Change 32.61% 49.88% 14436.92%
Cash From Operating Activities -$4.170M -$3.750M -$2.110M
YoY Change 46.32% 77.73% 51.8%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $90.00K $440.0K
YoY Change -79.55%
Acquisitions
YoY Change
Other Investing Activities $1.120M $2.840M $5.850M
YoY Change -186.82% -51.45%
Cash From Investing Activities $1.130M $2.730M $5.400M
YoY Change -187.6% -49.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -140.0K 2.210M 0.000
YoY Change -109.79% -100.0%
NET CHANGE
Cash From Operating Activities -4.170M -3.750M -2.110M
Cash From Investing Activities 1.130M 2.730M 5.400M
Cash From Financing Activities -140.0K 2.210M 0.000
Net Change In Cash -3.180M 1.190M 3.290M
YoY Change 17.34% -63.83% -275.0%
FREE CASH FLOW
Cash From Operating Activities -$4.170M -$3.750M -$2.110M
Capital Expenditures $10.00K $90.00K $440.0K
Free Cash Flow -$4.180M -$3.840M -$2.550M
YoY Change 46.67% 50.59% 83.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Investment Income Interest
InvestmentIncomeInterest
29828 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
17521 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25482 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26529 USD
us-gaap Interest Expense
InterestExpense
148505 USD
us-gaap Interest Expense
InterestExpense
USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-93195 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9008 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-306946 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-203810 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23202 USD
us-gaap Operating Expenses
OperatingExpenses
5372315 USD
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
us-gaap Profit Loss
ProfitLoss
-8929615 USD
us-gaap Profit Loss
ProfitLoss
-5381323 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2202398 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2029758 USD
us-gaap Operating Expenses
OperatingExpenses
8836420 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8836420 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5372315 USD
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32758116 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24135447 USD
CY2015Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12228 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1090791 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1382987 USD
htbx Clinical And Regulatory Expense
ClinicalAndRegulatoryExpense
5543231 USD
htbx Clinical And Regulatory Expense
ClinicalAndRegulatoryExpense
1959570 USD
us-gaap Net Income Loss
NetIncomeLoss
-8622669 USD
us-gaap Net Income Loss
NetIncomeLoss
-5177513 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7612393 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6432857 shares
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-37051 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8966666 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5381323 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-306946 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-203810 USD
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4729656 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
849359 USD
CY2014Q2 htbx Clinical And Regulatory Expense
ClinicalAndRegulatoryExpense
1113186 USD
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1014888 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
2977433 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2977433 USD
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
6546 USD
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12530 USD
CY2014Q2 us-gaap Interest Expense
InterestExpense
USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8659720 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5177513 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
587240 USD
CY2015Q2 htbx Clinical And Regulatory Expense
ClinicalAndRegulatoryExpense
3373758 USD
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
893242 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
4854240 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4854240 USD
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
20702 USD
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3865 USD
CY2015Q2 us-gaap Interest Expense
InterestExpense
73075 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-48508 USD
CY2015Q2 us-gaap Profit Loss
ProfitLoss
-4902748 USD
CY2015Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-189277 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-4713471 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8401159 shares
CY2015Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-16185 USD
CY2015Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4918933 USD
CY2015Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-189277 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19076 USD
CY2014Q2 us-gaap Profit Loss
ProfitLoss
-2958357 USD
CY2014Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-111442 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2846915 USD
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6452986 shares
CY2014Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
USD
CY2014Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2958357 USD
CY2014Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-111442 USD
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2846915 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11400870 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
786847 USD
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
302461 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-37051 USD
us-gaap Depreciation
Depreciation
21068 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
50074 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
59882 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
106762 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
20600 USD
us-gaap Share Based Compensation
ShareBasedCompensation
786847 USD
us-gaap Share Based Compensation
ShareBasedCompensation
497772 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
9375 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
11446 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-16487 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7737091 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1416385 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-398454 USD
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
50000 USD
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
10478 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-569974 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
68228 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
362523 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-182944 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-25364 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8210271 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4498671 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
12967509 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
9631543 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
10241275 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
3305972 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
103369 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
448234 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2622865 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
5877337 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11400870 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
302461 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13340984 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37719 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4566992 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5983377 USD
us-gaap Interest Paid
InterestPaid
98430 USD
us-gaap Interest Paid
InterestPaid
USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
12228 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2242575 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
USD
htbx Cashless Exercise Of Stock Warrants
CashlessExerciseOfStockWarrants
USD
htbx Cashless Exercise Of Stock Warrants
CashlessExerciseOfStockWarrants
143190 USD
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
203406 USD
dei Document Type
DocumentType
10-Q
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
625357 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
521988 USD
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
130391 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
76454 USD
CY2015Q2 us-gaap Depreciation
Depreciation
28325 USD
CY2014Q2 us-gaap Depreciation
Depreciation
18898 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1018590 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.04
dei Trading Symbol
TradingSymbol
HTBX
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30000 USD
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000 USD
CY2015Q2 us-gaap Accrued Rent Current
AccruedRentCurrent
56300 USD
us-gaap Depreciation
Depreciation
53937 USD
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
218299 USD
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
519092 USD
CY2014Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
51155 USD
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
USD
CY2015Q2 htbx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
660254 USD
CY2014Q4 htbx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
195721 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
205000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.23
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6522 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
173048 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.57
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1044020 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.03
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.864 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0166 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
615063 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.71
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2988921 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P16M3D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1640000 shares
CY2015Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
6.50
dei Entity Central Index Key
EntityCentralIndexKey
0001476963
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8405434 shares
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11100000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
HEAT BIOLOGICS, INC.

Files In Submission

Name View Source Status
0001553350-15-000845-index-headers.html Edgar Link pending
0001553350-15-000845-index.html Edgar Link pending
0001553350-15-000845.txt Edgar Link pending
0001553350-15-000845-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
htbx-20150630.xml Edgar Link completed
htbx-20150630.xsd Edgar Link pending
htbx-20150630_cal.xml Edgar Link unprocessable
htbx-20150630_def.xml Edgar Link unprocessable
htbx-20150630_lab.xml Edgar Link unprocessable
htbx-20150630_pre.xml Edgar Link unprocessable
htbx_10q.htm Edgar Link pending
htbx_ex31z1.htm Edgar Link pending
htbx_ex31z2.htm Edgar Link pending
htbx_ex32z1.htm Edgar Link pending
htbx_ex32z2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending